Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Neurotrophic Keratitis Treatment Market Size And Revenue Forecast Through 2030
The market for treating neurotrophic keratitis has experienced substantial expansion lately. Projections indicate a significant rise from $1.47 billion in 2025 to $1.99 billion in 2026, reflecting a compound annual growth rate (CAGR) of 36.1%. Factors contributing to this growth during the preceding period include the escalating occurrence of diabetes-associated corneal issues, a greater number of herpes simplex eye infections, the proliferation of specialized ophthalmology clinics, enhanced recognition of neurotrophic keratitis by medical professionals, and an increase in inpatient eye care offerings.
The market for treating neurotrophic keratitis is projected to experience rapid expansion over the coming years, reaching an estimated $6.78 billion by 2030 with a compound annual growth rate of 35.8%. This projected growth is fueled by several key factors, including progress in regenerative treatments for eye conditions, the increasing authorization of drugs based on recombinant human nerve growth factor (rhNGF), a growing elderly population susceptible to nerve degradation, heightened investment in research for rare eye diseases, and improved availability of sophisticated eye care services in developing economies. During this forecast period, significant trends are anticipated to shape the market, such as a greater embrace of rhNGF therapies, a preference for less invasive methods for corneal repair, a stronger emphasis on detecting and addressing the condition in its early stages, the development of at-home eye treatment options, and innovations in preserving amniotic membranes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp
Neurotrophic Keratitis Treatment Market Growth Drivers And Industry Catalysts
The increasing incidence of various ocular conditions is anticipated to be a primary catalyst for the expansion of the neurotrophic keratitis treatment sector. These eye ailments encompass a broad spectrum of disorders impacting ocular structure and function, potentially resulting in diminished sight or complete blindness. Several factors contribute to the escalating prevalence of eye diseases, including demographic shifts towards an older population, evolving lifestyle habits, and a greater number of individuals developing chronic illnesses such as diabetes. Treatments for neurotrophic keratitis contribute to maintaining eye health by enhancing corneal sensitivity, facilitating the healing process, averting infections, and providing relief from discomfort. Illustrating this trend, the World Health Organization (WHO), a UN agency headquartered in Switzerland, reported in August 2023 that approximately 2.2 billion individuals worldwide experience vision impairment, either near or far, with a significant portion, 1 billion cases, being either preventable or lacking adequate treatment. Refractive errors and cataracts are identified as the principal global contributors to vision loss, yet only a fraction of affected individuals, specifically 36% for refractive error-related distance impairment and a mere 17% for cataract-related impairment, have accessed suitable medical interventions. Consequently, the widespread rise in eye diseases is directly fueling the growth trajectory of the market for neurotrophic keratitis treatments.
Neurotrophic Keratitis Treatment Market Segment Landscape And Growth Potential
The neurotrophic keratitis treatment market covered in this report is segmented –
1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments
2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations
3) By Application: Stage I, Stage II, Stage III
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution
3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane
4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty
5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses
#Neurotrophic Keratitis Treatment Market Trends Influencing Long-Term Demand
Within the neurotrophic keratitis market, leading entities are prioritizing the innovation of sophisticated gene-therapy methodologies, specifically reusable eye-drop treatments, with the dual aims of enhancing corneal repair, ensuring persistent nerve growth factor (NGF) levels, and alleviating the patient’s therapeutic demands. This reusable eye-drop gene therapy represents an innovative treatment strategy wherein genes responsible for NGF production are directly introduced into the cornea, facilitating extended NGF synthesis and fostering nerve regrowth throughout the treatment period. As an illustration, in July 2025, Krystal Biotech, a biotechnology firm headquartered in the United States, reported the administration of the initial dose to a participant in its EMERALD 1 trial, a Phase 1/2 study designed as a randomized, double-masked, and placebo-controlled investigation enrolling a maximum of 27 adult patients diagnosed with stage 2 or 3 neurotrophic keratitis. The investigational therapy, KB801, is scheduled for administration twice weekly over an eight-week duration, with the objective of safely accelerating corneal healing while markedly decreasing the treatment frequency compared to current recombinant NGF eye drops, which require application six times daily.
Neurotrophic Keratitis Treatment Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV
Access The Complete Neurotrophic Keratitis Treatment Market Report:
Neurotrophic Keratitis Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North Americawas the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model